
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5013730/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Bidirectional association between systemic lupus erythematosus and macrophage activation syndrome: a nationwide population-based study. Rheumatology, 2022, 61, 1123-1132.	0.9	5
2	The effectiveness of tocilizumab in treating refractory adult-onset Still's disease with dichotomous phenotypes: IL-18 is a potential predictor of therapeutic response. Clinical Rheumatology, 2022, 41, 557-566.	1.0	7
3	Association of tumor necrosis factorâ€Î± inhibitors and liver cirrhosis in patients with rheumatoid arthritis: A nationwide populationâ€based nested caseâ€control study. International Journal of Rheumatic Diseases, 2022, 25, 327-334.	0.9	3
4	Immunogenicity, Effectiveness, and Safety of COVID-19 Vaccines in Rheumatic Patients: An Updated Systematic Review and Meta-Analysis. Biomedicines, 2022, 10, 834.	1.4	16
5	The BASDAI Cut-Off for Disease Activity Corresponding to the ASDAS Scores in a Taiwanese Cohort of Ankylosing Spondylitis. Frontiers in Medicine, 2022, 9, .	1.2	6
6	Alantolactone alleviates collagen-induced arthritis and inhibits Th17 cell differentiation through modulation of STAT3 signalling. Pharmaceutical Biology, 2021, 59, 132-143.	1.3	11
7	Factors associated with risk of major adverse cardiovascular events in patients with rheumatoid arthritis: a nationwide, population-based, case-control study. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110308.	1.2	7
8	Cardiolipin interacts with betaâ€2â€glycoprotein I and forms an open conformation–Mechanisms analyzed using hydrogen/deuterium exchange. Protein Science, 2021, 30, 927-939.	3.1	9
9	Autoimmune and Rheumatic Manifestations Associated With COVID-19 in Adults: An Updated Systematic Review. Frontiers in Immunology, 2021, 12, 645013.	2.2	75
10	Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: Analysis from the TRA Clinical Electronic Registry. PLoS ONE, 2021, 16, e0250877.	1.1	17
11	CARD8 SNP rs11672725 Identified as a Potential Genetic Variant for Adult-Onset Still's Disease. Life, 2021, 11, 382.	1.1	4
12	Kurarinone Attenuates Collagen-Induced Arthritis in Mice by Inhibiting Th1/Th17 Cell Responses and Oxidative Stress. International Journal of Molecular Sciences, 2021, 22, 4002.	1.8	19
13	Crassolide Suppresses Dendritic Cell Maturation and Attenuates Experimental Antiphospholipid Syndrome. Molecules, 2021, 26, 2492.	1.7	8
14	The Association of ATG16L1 Variations with Clinical Phenotypes of Adult-Onset Still's Disease. Genes, 2021, 12, 904.	1.0	4
15	Association of the Risk of Primary Sjögren's Syndrome With Fibrocystic Breast Disease: A Nationwide, Population-Based Study. Frontiers in Medicine, 2021, 8, 704593.	1.2	2
16	MicroRNA-223 inhibits neutrophil extracellular traps formation through regulating calcium influx and small extracellular vesicles transmission. Scientific Reports, 2021, 11, 15676.	1.6	25
17	Dendritic Cells and Antiphospholipid Syndrome: An Updated Systematic Review. Life, 2021, 11, 801.	1.1	5
18	Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine. JAMA Network Open, 2021, 4, e2128544.	2.8	46

#	Article	IF	CITATIONS
19	Change of Renal Gallium Uptake Correlated with Change of Inflammation Activity in Renal Pathology in Lupus Nephritis Patients. Journal of Clinical Medicine, 2021, 10, 4654.	1.0	1
20	The relationship between exposure to polycyclic aromatic hydrocarbons and adult atopic dermatitis. Asian Pacific Journal of Allergy and Immunology, 2021, , .	0.2	2
21	GAP Score and CA-153 Associated with One-Year Mortality in Anti-MDA-5 Antibody-Positive Patients: A Real-World Experience. Journal of Clinical Medicine, 2021, 10, 5241.	1.0	8
22	ANA positivity and complement level in pleural fluid are potential diagnostic markers in discriminating lupus pleuritis from pleural effusion of other aetiologies. Lupus Science and Medicine, 2021, 8, e000562.	1.1	2
23	Metabolic disturbances in systemic lupus erythematosus evaluated with UPLC-MS/MS. Clinical and Experimental Rheumatology, 2021, , .	0.4	0
24	Association between periodontitis and the risk of inadequate disease control in patients with rheumatoid arthritis under biological treatment. Journal of Clinical Periodontology, 2020, 47, 148-159.	2.3	2
25	Risk of interstitial lung disease in patients with newly diagnosed systemic autoimmune rheumatic disease: A nationwide, population-based cohort study. Seminars in Arthritis and Rheumatism, 2020, 50, 840-845.	1.6	20
26	Degraded microarchitecture by low trabecular bone score is associated with prevalent vertebral fractures in patients with systemic lupus erythematosus. Archives of Osteoporosis, 2020, 15, 54.	1.0	11
27	Antitumour necrosis factor-α agents and development of new-onset cirrhosis or non-alcoholic fatty liver disease: a retrospective cohort. BMJ Open Gastroenterology, 2020, 7, e000349.	1.1	23
28	Phloretin alleviates dinitrochlorobenzene-induced dermatitis in BALB/c mice. International Journal of Immunopathology and Pharmacology, 2020, 34, 205873842092944.	1.0	9
29	Gender difference in ASAS HI among patients with ankylosing spondylitis. PLoS ONE, 2020, 15, e0235678.	1.1	21
30	Gender difference in ASAS HI among patients with ankylosing spondylitis. , 2020, 15, e0235678.		0
31	Gender difference in ASAS HI among patients with ankylosing spondylitis. , 2020, 15, e0235678.		0
32	Gender difference in ASAS HI among patients with ankylosing spondylitis. , 2020, 15, e0235678.		0
33	Gender difference in ASAS HI among patients with ankylosing spondylitis. , 2020, 15, e0235678.		0
34	Gender difference in ASAS HI among patients with ankylosing spondylitis. , 2020, 15, e0235678.		0
35	Gender difference in ASAS HI among patients with ankylosing spondylitis. , 2020, 15, e0235678.		0
36	Ten-year fracture risk by FRAX and osteoporotic fractures in patients with systemic autoimmune diseases. Lupus, 2019, 28, 945-953.	0.8	16

#	Article	IF	CITATIONS
37	Relationship between exposure to air pollutants and development of systemic autoimmune rheumatic diseases: a nationwide population-based case–control study. Annals of the Rheumatic Diseases, 2019, 78, 1288-1291.	0.5	9
38	Combination immunosuppressant therapy and lupus nephritis outcome: a hospital-based study. Lupus, 2019, 28, 658-666.	0.8	5
39	Apoptosis in patients with primary antiphospholipid antibody syndrome. International Journal of Rheumatic Diseases, 2019, 22, 677-685.	0.9	7
40	A case of adult onset Still's disease with mutations of the MEFV gene who is partially responsive to colchicine. Medicine (United States), 2018, 97, e0333.	0.4	7
41	Reduced frontal activity during a verbal fluency test in fibromyalgia: A near-infrared spectroscopy study. Journal of Clinical Neuroscience, 2018, 50, 35-40.	0.8	16
42	Association between autophagy and inflammation in patients with rheumatoid arthritis receiving biologic therapy. Arthritis Research and Therapy, 2018, 20, 268.	1.6	38
43	Gender Difference in the Relationship of Albuminuria and Arterial Stiffness in Chinese Adults - a 6.6-Year Follow-Up Longitudinal Study. Kidney and Blood Pressure Research, 2018, 43, 1479-1487.	0.9	3
44	Psoriatic patients with chronic viral hepatitis do not have an increased risk of liver cirrhosis despite long-term methotrexate use: Real-world data from a nationwide cohort study in Taiwan. Journal of the American Academy of Dermatology, 2018, 79, 652-658.	0.6	13
45	Tolerogenic β2-glycoprotein I DNA vaccine and FK506 as an adjuvant attenuates experimental obstetric antiphospholipid syndrome. PLoS ONE, 2018, 13, e0198821.	1.1	4
46	Induction therapy for membranous lupus nephritis: a systematic review and network metaâ€analysis. International Journal of Rheumatic Diseases, 2018, 21, 1163-1172.	0.9	13
47	Adult atopic dermatitis and exposure to air pollutants—a nationwide population-based study. Annals of Allergy, Asthma and Immunology, 2017, 118, 351-355.	0.5	48
48	Elevated Expression of the NLRP3 Inflammasome and Its Correlation with Disease Activity in Adult-onset Still Disease. Journal of Rheumatology, 2017, 44, 1142-1150.	1.0	53
49	Inhibitory effects of propofol on Th17 cell differentiation. Immunopharmacology and Immunotoxicology, 2017, 39, 211-218.	1.1	2
50	Upregulation of circulating microRNA-134 in adult-onset Still's disease and its use as potential biomarker. Scientific Reports, 2017, 7, 4214.	1.6	26
51	Plasma levels of high-mobility group box 1 and soluble receptor for advanced glycation end products in primary antiphospholipid antibody syndrome patients. PLoS ONE, 2017, 12, e0178404.	1.1	8
52	The risk of tuberculosis disease in rheumatoid arthritis patients on biologics and targeted therapy: A 15-year real world experience in Taiwan. PLoS ONE, 2017, 12, e0178035.	1.1	51
53	Methotrexate is not associated with increased liver cirrhosis in a population-based cohort of rheumatoid arthritis patients with chronic hepatitis C. Scientific Reports, 2016, 6, 33104.	1.6	9
54	Methotrexate is not associated with increased liver cirrhosis in a population-based cohort of rheumatoid arthritis patients with chronic hepatitis B. Scientific Reports, 2016, 6, 22387.	1.6	15

#	Article	IF	CITATIONS
55	Betahistine attenuates murine collagen-induced arthritis by suppressing both inflammatory and Th17 cell responses. International Immunopharmacology, 2016, 39, 236-245.	1.7	3
56	Suicidal drug overdose in patients with systemic lupus erythematosus, a nationwide population-based case-control study. Lupus, 2016, 25, 199-203.	0.8	10
57	Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up. Rheumatology, 2016, 55, 143-148.	0.9	40
58	Suicide Attempts in Patients With Systemic Lupus Erythematosus: A Single-Center Experience and Literature Review. Psychosomatics, 2015, 56, 190-195.	2.5	11
59	Measuring serum levels of high-mobility group box 1 by enzyme-linked immunosorbent assay does not identify bacterial infections in patients with systemic lupus erythematosus. Lupus, 2014, 23, 926-934.	0.8	2
60	Metabolic disturbances in systemic lupus erythematosus evaluated with UPLC-MS/MS. Clinical and Experimental Rheumatology, 0, , .	0.4	3